Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Resistance to Immunotoxins in Cancer Therapy

Buch | Hardcover
XVI, 249 Seiten
2015 | 2015
Springer International Publishing (Verlag)
978-3-319-17274-3 (ISBN)

Lese- und Medienproben

Resistance to Immunotoxins in Cancer Therapy -
CHF 149,75 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Rama Shanker Verma, Ph.D., is Professor, Department of Biotechnology, the Indian Institute of Technology. Professor Verma specializes in the development of novel immunotoxins for cancer therapies. He has published 76 scientific articles, five book chapters, and several conference abstracts. He is an Elected Fellow, the Association of Microbiologists of India an Elected Fellow, the Society for Applied Biotechnology. He received the award for Excellence in Medical Biotechnology from the Society for Applied Biotechnology.

1 Targeted Cancer Therapy: History and Development of Immunotoxins.-2 Immunotoxins, Resistance and Cancer Stem Cells: Future Perspective.-3 Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins.-4 Cell Signaling and Resistance to Immunotoxins.-5 Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms.-6 Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins .-7 Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy .-8 Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins.-9 Therapeutic Impact of Immune Responses in Cancer.

Erscheint lt. Verlag 27.6.2015
Reihe/Serie Resistance to Targeted Anti-Cancer Therapeutics
Zusatzinfo XVI, 249 p. 22 illus., 19 illus. in color.
Verlagsort Cham
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Mikrobiologie / Infektologie / Reisemedizin
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Studium
Schlagworte antibacterial drug resistance • antibodies • chemoresistance • drug development • drug resistance • immunotoxin resistance
ISBN-10 3-319-17274-3 / 3319172743
ISBN-13 978-3-319-17274-3 / 9783319172743
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
und Erste Hilfe an Bord

von Jürgen Graf; Jochen Hinkelbein

Buch | Softcover (2024)
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft
CHF 55,90